A) Cell cycle analysis by flow cytometry of CTR (untreated) and PTX treated ASCs (1μM for 6 hours). Adherent and not adherent cells were processed for PI staining to evaluate cell cycle. B) Cytofluorimetric bi-parametric analysis of the annexin V versus PI staining assay. The percentage reported in the annexin V+/PI+ region of each histogram represents the apoptotic cells. C, D) MTT assay of ASCs and CG5 treated with different concentrations of PTX for 6 hours, respectively. E) CG5 cells were treated with PTX free at 1 μM or with conditioned medium previously obtained by PTX primed ASCs at 1 μM. Adherent and not adherent cells were processed for cell cycle analysis. The percentages of cells in the different phases of cell cycle were reporte...
(A) Cell cycle analysis of untreated and PTX treated MDA-MB-157 and APC shRNA1 cells using flow cyto...
A) Tumor growth curve of CG5 cells (1x106) co-injected i.m.in nude mice (5 mice/group) with ASCs (1x...
<p>(A) The schematic illustrates the amino acid sequence of each CPPP derivative. (B–C) MDA-MB 468 c...
A) The inhibitory activity of PTX-loaded ASCs on CG5 proliferation by clonogenic assay. ASCs were pr...
A) Cell cycle analysis by flow cytometry of adherent and not adherent cells processed for PI stainin...
Cytotoxic activity of PTX-loaded ASC conditioned medium on CG5 human breast cancer cells (MTT assay)...
A) Representative images of cultured ASCs treated with PTX 1μM for 6 hours. B) Flow cytometric analy...
<p>(A) Cell viability was assessed by XTT colorimetric assay performed at 24 h and 7 days post Plasm...
<p>Cells grown in 6-well plates were treated with A) 0.3% DMSO, B) 0.5 µM PTX C) 10 µM CYA, D) 25 µM...
<p>(a) Apoptosis rates of C-kit<sup>+</sup> CSCs were measured using the Annexin V-FITC/PI staining ...
<p>A549Pt and A549cisR cells were treated for 48 hours with 5 μM and 5 μM or 25 μM cisplatin (cisPt)...
<p><b>A)</b> Annexin V-FITC staining was used to detect apoptosis by flow analysis in control (DMSO)...
<p>(A) Cell viability examined by trypan blue exclusion in LNCaP (LN), LNb4 and PC-3 cells. (B) Dete...
BACKGROUND: To study the apoptotic process in time, we used the following flow cytometric (FCM) tech...
<p>Cells were incubated with cisplatin (300 ng/ml), cetuximab (200 µg/ml), and cisplatin (300 ng/ml)...
(A) Cell cycle analysis of untreated and PTX treated MDA-MB-157 and APC shRNA1 cells using flow cyto...
A) Tumor growth curve of CG5 cells (1x106) co-injected i.m.in nude mice (5 mice/group) with ASCs (1x...
<p>(A) The schematic illustrates the amino acid sequence of each CPPP derivative. (B–C) MDA-MB 468 c...
A) The inhibitory activity of PTX-loaded ASCs on CG5 proliferation by clonogenic assay. ASCs were pr...
A) Cell cycle analysis by flow cytometry of adherent and not adherent cells processed for PI stainin...
Cytotoxic activity of PTX-loaded ASC conditioned medium on CG5 human breast cancer cells (MTT assay)...
A) Representative images of cultured ASCs treated with PTX 1μM for 6 hours. B) Flow cytometric analy...
<p>(A) Cell viability was assessed by XTT colorimetric assay performed at 24 h and 7 days post Plasm...
<p>Cells grown in 6-well plates were treated with A) 0.3% DMSO, B) 0.5 µM PTX C) 10 µM CYA, D) 25 µM...
<p>(a) Apoptosis rates of C-kit<sup>+</sup> CSCs were measured using the Annexin V-FITC/PI staining ...
<p>A549Pt and A549cisR cells were treated for 48 hours with 5 μM and 5 μM or 25 μM cisplatin (cisPt)...
<p><b>A)</b> Annexin V-FITC staining was used to detect apoptosis by flow analysis in control (DMSO)...
<p>(A) Cell viability examined by trypan blue exclusion in LNCaP (LN), LNb4 and PC-3 cells. (B) Dete...
BACKGROUND: To study the apoptotic process in time, we used the following flow cytometric (FCM) tech...
<p>Cells were incubated with cisplatin (300 ng/ml), cetuximab (200 µg/ml), and cisplatin (300 ng/ml)...
(A) Cell cycle analysis of untreated and PTX treated MDA-MB-157 and APC shRNA1 cells using flow cyto...
A) Tumor growth curve of CG5 cells (1x106) co-injected i.m.in nude mice (5 mice/group) with ASCs (1x...
<p>(A) The schematic illustrates the amino acid sequence of each CPPP derivative. (B–C) MDA-MB 468 c...